CureLab Oncology, a clinical-stage biotech company, announced on Thursday that it has named Dr Aubrey C Galloway as its new chief medical officer (CMO).
In the new role, Dr Galloway will manage the clinical development strategy for the company's lead investigational compound, Elenagen, and new forms of treatment that CureLab is presently developing.
Dr Galloway is a cardiac surgeon and the Seymour Cohn Professor of Cardiothoracic Surgery at NYU Langone Health. He has directed the department's Cardiac Surgery Research and Clinical Trials program for more than 20 years and worked as Chair of the Department of Cardiothoracic Surgery for 15 years.
BRAVO study confirms blue light cystoscopy reduces bladder cancer recurrence risk
Cantargia enrolls first patient in leukemia study with nadunolimab
OsteoCentric Technologies partners with Globus Medical to expand innovative implant technology
Arvinas and Pfizer report positive Phase 3 results for vepdegestrant in breast cancer trial
PHI advances Next-Generation HoloMonitor CellSync for cell and gene therapy
Health Canada approves Johnson & Johnson therapy for advanced EGFR-mutated lung cancer
Immunome initiates Phase 1 trial of ROR1-targeted ADC IM-1021
NeoGenomics acquires Pathline to strengthen Northeast oncology testing reach
Sun Pharmaceutical acquires Checkpoint Therapeutics
Bantam Pharmaceutical expands Phase 1 trial of BTM-3566 into Canada